Cargando…

HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia

Owing to the recent emergence of drug resistance to Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic leukemia (CLL) treatment, it is crucial to identify alternative therapeutic targets. Therefore, we aimed to identify therapeutic options for CLL besides BTK. We identified that HIF1A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Wancheng, Liang, Daomiao, Wang, Peilong, Yin, Le, Zhang, Huifang, Xing, Cheng, Huang, Zineng, Wu, Yinghua, Li, Heng, Cheng, Zhao, Xiao, Xiaojuan, Liu, Jing, Wang, Zhihua, Peng, Hongling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229586/ https://www.ncbi.nlm.nih.gov/pubmed/35745653 http://dx.doi.org/10.3390/ph15060734

Ejemplares similares

Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma
por: Zhu, Shicong, et al.
Publicado: (2023)

Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma
por: Xing, Cheng, et al.
Publicado: (2023)

Variants of the Low Oxygen Sensors EGLN1 and HIF-1AN Associated with Acute Mountain Sickness
por: Zhang, Enhao, et al.
Publicado: (2014)

EGLN1 prolyl hydroxylation of hypoxia-induced transcription factor HIF1α is repressed by SET7-catalyzed lysine methylation
por: Tang, Jinhua, et al.
Publicado: (2022)

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
por: Astuti, Dewi, et al.
Publicado: (2011)

Suppression of Glioma Progression by Egln3
por: Sciorra, Vicki A., et al.
Publicado: (2012)

Convergent evolution on the hypoxia-inducible factor (HIF) pathway genes EGLN1 and EPAS1 in high-altitude ducks
por: Graham, Allie M., et al.
Publicado: (2019)

An EGLN1 mutation may regulate hypoxic response in cyanotic congenital heart disease through the PHD2/HIF-1A pathway
por: Zhou, Yuanlin, et al.
Publicado: (2018)

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience
por: Gangat, Naseema, et al.
Publicado: (2022)

Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene
por: Moore, Joseph A., et al.
Publicado: (2020)

TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer
por: Xiang, Jinfeng, et al.
Publicado: (2018)

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation
por: Koivunen, Peppi, et al.
Publicado: (2012)

Congenital erythrocytosis – discover of a new mutation in the EGLN1 gene
por: Barradas, João, et al.
Publicado: (2018)

EglN2 positively regulates mitochondrial function in breast cancer
por: Zhang, Jing, et al.
Publicado: (2015)

Effect of EGLN1 Genetic Polymorphisms on Hemoglobin Concentration in Andean Highlanders
por: Yasukochi, Yoshiki, et al.
Publicado: (2020)

MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer
por: Wang, Yicun, et al.
Publicado: (2019)

Proteomic profiling of plasma exosomes from patients with B-cell acute lymphoblastic leukemia
por: Zhu, Shicong, et al.
Publicado: (2022)

Genetic Analysis of EGLN1 C127S Variant in Taiwanese Parkinson's Disease
por: Chiang, Han-Lin, et al.
Publicado: (2020)

Genome-Wide Knockout Screen Identifies EGLN3 Involving in Ammonia Neurotoxicity
por: Li, Jiequn, et al.
Publicado: (2022)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
por: Zhao, Yan, et al.
Publicado: (2021)

A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia
por: Gong, Han, et al.
Publicado: (2022)

EGLN1 induces tumorigenesis and radioresistance in nasopharyngeal carcinoma by promoting ubiquitination of p53 in a hydroxylase-dependent manner
por: Sun, Lu, et al.
Publicado: (2022)

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
por: Zhao, Yan, et al.
Publicado: (2023)

Osteocyte Egln1/Phd2 links oxygen sensing and biomineralization via FGF23
por: Noonan, Megan L., et al.
Publicado: (2023)

Association between an indel polymorphism within the distal promoter of EGLN2 and cancer risk: An updated meta‐analysis
por: Zhang, Shulong, et al.
Publicado: (2019)

EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes
por: Jiang, Yiqun, et al.
Publicado: (2017)

Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
por: Rahimi, Nahid, et al.
Publicado: (2020)

Egln1(Tie2Cre) Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1(Tie2Cre) Mice as a Useful PAH Model
por: Peng, Yi, et al.
Publicado: (2023)

Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth
por: Jin, Ying, et al.
Publicado: (2022)

Combined genetic effects of EGLN1 and VWF modulate thrombotic outcome in hypoxia revealed by Ayurgenomics approach
por: Aggarwal, Shilpi, et al.
Publicado: (2015)

Comprehensive bioinformatics analysis for MEF2 family genes in gastric cancer
por: Zhu, Hongkai, et al.
Publicado: (2022)

Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2010)

Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase
por: Zheng, Xingnan, et al.
Publicado: (2014)

EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population
por: Ding, Yipeng, et al.
Publicado: (2015)

Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis
por: Delamare, Marine, et al.
Publicado: (2023)

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells
por: Guo, Wancheng, et al.
Publicado: (2021)

Polymorphisms in the Egl nine homolog 3 (EGLN3) and Peroxisome proliferator activated receptor-alpha (PPARα) genes and their correlation with hypoxia adaptation in Tibetan chickens
por: Zhong, ChengLin, et al.
Publicado: (2018)

Correction: Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated EGLN2-Mediated Oxygen-Sensing Response
por: Koeman, Julie M., et al.
Publicado: (2008)

Association of EGLN1 genetic polymorphisms with SpO(2) responses to acute hypobaric hypoxia in a Japanese cohort
por: Yasukochi, Yoshiki, et al.
Publicado: (2018)

EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor
por: Takada, Mamoru, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p5m4lcmdbta6a97kr6irbqov59